CAV-PaclitaxelNCT07929766
LDE-Paclitaxel for Cardiac Allograft Vasculopathy: A Pilot Study
StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Feasibility - strict protocol completion
Timeframe: From the first infusion through follow-up angiography/IVUS (approximately 1 month after the 6th infusion; about 5 months)
Safety - serious or grade ≥3 adverse events related to study drug
Timeframe: From baseline angiography/IVUS through 30 days after the last infusion or 7 days after follow-up angiography/IVUS, whichever is later (about 5 months)
Secondary (9)
Feasibility - pragmatic protocol completion
Adverse events by grade, seriousness and relatedness
Treated acute rejection
Clinically relevant infection
Change in percent atheroma volume (PAV)
Show 4 moreShow less
Change in normalized total atheroma volume (TAVnorm)
Change in maximal intimal thickness (MIT)
Change in minimal lumen area (MLA)
Angiographic cardiac allograft vasculopathy grade
Arms and interventions
LDE-paclitaxelExperimental
Paclitaxel 175 mg/m² body surface area carried in LDE, intravenous infusion over 2 hours, every 3 weeks for 6 cycles.
Placebo (LDE)Placebo comparator
LDE without paclitaxel, intravenous infusion over 2 hours, every 3 weeks for 6 cycles.
Drugs: LDE-Paclitaxel, Placebo (LDE)
Sites
1 site in 1 country
- Heart Institute (InCor), Hospital das Clínicas, University of São Paulo Medical SchoolSão Paulo, São Paulo, Brazil